
Please try another search
Wall Street seems to have eyes only for two things at the moment: the potential next move by the Federal Reserve and geopolitical tensions between Russia and Ukraine. Meanwhile, many stocks and...
Pre-commercial biotech group Novavax’s stock is down more than 45% in January. The FDA has not yet authorized Novavax’s vaccine for use in the US. Long-term investors could consider buying...
A number of health-care and biotech shares have recently been in the spotlight. In early October, Merck (NYSE:MRK)—covered in early November—gave a positive update on molnupiravir, a...
It was what I call a good consolidation day on Tuesday. The market had an orderly retrace and came back at the end of the day closing mixed. The blue chips were stronger than NASDAQ, for sure. A lot...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review